Dicerna Pharmaceuticals, Inc.. (11/8/17). "Press Release: Dicerna to Present at the Stifel 2017 Healthcare Conference". Cambridge, MA.

	Region	New York, NY
	Country	United States (USA)
	Organisation	Dicerna Pharmaceuticals Inc. (Nasdaq: DRNA)
	Organisation 2	Stifel, Nicolaus & Company Inc.
	Group	Stifel (Group)
	Product	Stifel Healthcare Conference 2017 New York
	Product 2	GalXC™ RNAi technology platform
	Index term	Dicerna Pharmaceuticals–Stifel: investor conference, 201711 supply service Dicerna presents at Stifel 2017 Healthcare Conference in NY
	Person	Fambrough, Douglas M. (Dicerna Pharmaceuticals 201711 CEO)
	Person 2	Schwartz, Paula (Rx Communications 201711)

Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 2:45 p.m. ET. The conference will be held at the Lotte New York Palace Hotel in New York City.

A live webcast of the presentation can be accessed on the Investors & Media section on the Dicerna website at www.dicerna.com. An archived replay of the webcast will be available on the Company's website after the conference.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery and development of innovative, subcutaneously delivered RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where connections between target gene and diseases are well understood and documented. Dicerna intends to discover, develop and commercialize novel therapeutics either on its own or in collaboration with pharmaceutical partners. For more information, please visit www.dicerna.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005171/en/

Investors:
Rx Communications Group
Paula Schwartz, 917-322-2216
pschwartz@rxir.com

or

Media:
SmithSolve
Alex Van Rees, 973-442-1555 ext. 111
alex.vanrees@smithsolve.com

Record changed: 2023-06-05